Rolland-Yves Mauvernay

Immunexpress, Inc. engages in development of revolutionary molecular diagnostics. The firm's SeptiCyte technology quantifies specific and multiple molecular markers from the patient?s own immune system for earlier detection and severity assessment of sepsis, as well as the better timing of drugs and other therapies. The company was founded by Richard Bruce Brandon, Roslyn Brandon and Mervyn Rees Thomas in and is headquartered in

Part of Novonesis A/S, Delta Biotechnology Ltd. is a British company that produces and markets a range of valuable proteins from yeast using low-cost manufacturing technologies. The company is based in Windlesham, UK. Delta Biotechnology was acquired by Novozymes A/S on July 06, 2006.

Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia.

Molecular Devices LLC engages in the provision of bioanalytical solutions for protein and cell biology in life science research, pharmaceutical, and bio-therapeutic development. Its product portfolio includes platforms for screening, genomic and cellular analysis, colony selection, and microplate detection. The company was founded by Harden M. McConnell in July, 1983 and is headquartered in San Jose, CA.

Capital Investment & Brokerage Co. is a broker/dealer headquartered in Amman, Jordan. It was founded in 19995 and is a subsidiary of Capital Bank of Jordan (ASE: EXFB). The firm provides a range of brokerage services to various clients.

Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.

Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland.

Iktos SAS is a French company that specializes in generative modeling for drug discovery. The company is based in Paris, France and was founded in 2016 by Nicolas Do Huu, Yann Gaston-Mathé, and Quentin Perron. The company's offerings include professional services, research collaborations, partnerships, and software and SaaS licenses. The company's innovative technology platform includes generative modeling solutions with built-in synthetic accessibility. Contact them at contact@iktos.com for more details. Yann Gaston-Mathé has been the CEO since 2016.

Novadiscovery SAS develops mathematical model and artificial intelligence solutions for the healthcare sector. It offers risk management analytic tools for medical research programs and clinical trials. The company was founded by Fr?d?ric Cogny, Jean-Pierre Boissel, and Fran?ois-Henri Boissel in 2010 and is headquartered in Lyon, France.

Kaiku Health Oy engages in the provision of digital health interventions for cancer patients. It offers patient-reported outcome monitoring and intelligent system tracking. The company was founded by Kaarlo Haikonen, Joel Lehikoinen, Henri Virtanen, Otto Seiskari and Lauri Sippola in 2012 and is headquartered in Helsinki, Finland.

Innomedica is an international business consulting company serving the biotechnology and pharmaceutical industries. It provides a range of professional business development and project management services to its clients in both the public and private sectors. Innomedica's service portfolio includes Business Development, Licensing & Partnering, Japan Markets and Project Management. It is active on a global basis, though it specializes in the North European and Japanese markets. Its people are its main asset. Its success is based on leveraging the experience of professionals from different disciplines to deliver value to its clients. Its team portrays backgrounds from experienced business people to skilled lawyers and biomedical scientists. Innomedica was founded in 1997, and is a privately held company. Its client base covers both private and public sectors, both large and small.

Med Discovery SA is a Swiss biopharmaceutical company that develops treatments for cancers. The private company was founded by David Luc Deperthes.